Pretreatment with 8-methoxypsoralen, a potent human CYP2A6 inhibitor, strongly inhibits lung tumorigenesis induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in female A/J mice.

Content Provider	Semantic Scholar
Author	Takeuchi, Hijiri Saoo, Kousuke Yokohira, Masanao Ikeda, Mico Maeta, Hajime Miyazaki, Masafumi Yamazaki, Hiroshi Kamataki, Tetsuya Imaida, Katsumi
Copyright Year	2003
Abstract	Human CYP2A6 has been recognized as being involved in the mutagenic activation of promutagens such as the tobacco-specific nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK). Methoxsalen (8-methoxypsoralen) was reported to inhibit CYP2A6. In the present study, the inhibitory effects of methoxsalen on NNK-induced lung tumorigenesis in female A/J mice were examined. Female A/J mice were treated with methoxsalen at doses of 50 or 12.5 mg/kg body weight, given by stomach tube, daily for 3 days. One h after the final treatment, NNK was injected i.p. at a dose of 2 mg/mouse. The experiments were terminated 16 weeks after the first methoxsalen treatment, and lung adenomas were analyzed. Pretreatment of methoxsalen significantly reduced tumor incidence from 93.8% to 16.7% (50 mg/kg) and 20.0% (12.5 mg/kg), and tumor multiplicity from 5.97 to 0.23 (50 mg/kg) and 0.25 (12.5 mg/kg) tumors/mouse. These results clearly demonstrated that methoxsalen, a potent human CYP2A6 inhibitor, is a strong chemopreventive agent against NNK-induction of lung tumorigenesis.
File Format	PDF HTM / HTML
PubMed reference number	14633670
Journal	Medline
Volume Number	63
Issue Number	22
Alternate Webpage(s)	http://cancerres.aacrjournals.org/content/canres/63/22/7581.full.pdf
Journal	Cancer research
Language	English
Access Restriction	Open
Content Type	Text
Resource Type	Article